Texas profits from 4th best state economy in the U.S., report finds

report

Everything is better in Texas, including the state economy. Photo by via Getty Images

Despite growing sentiments that the U.S. is on a path towards a recession, Texas is pulling a lot of weight as one of the best state economies in the nation, according to a new annual report from WalletHub.

Texas' strong state economy ranked No. 4, with Washington (No. 1), Utah (No. 2), and Massachusetts (No. 3) claiming the top three spots.

The study analyzed all 50 states and the District of Columbia based on 28 metrics to determine the "Best & Worst State Economies" in 2024. Each state was ranked across three major categories: Economic activity, economic health, and innovation potential.

The Lone Star State earned a score of 60.08 out of 100 possible points, nipping at the heels of Massachusetts, which earned 61.52 points. For comparison, Washington claimed its No. 1 title with a score of 71.10.

Here's how Texas performed within the three major categories in the study:

  • No. 2 – Economic activity
  • No. 7 – Economic health
  • No. 24 – Innovation potential

Most notably, Texas tied with Louisiana for the No. 1 most exports per capita nationwide, according to the report's findings. Texas also had the second-highest change in GDP (gross domestic product) from 2022 to 2023.

Texas has the 10th highest amount of "startup activity," which WalletHub calculated as the rate of newly established firms. Texas also scored No. 10 in the country for its annual median household income of $75,647.

Nonfarm payrolls – defined as the number of workers employed in the U.S. (excluding those the farming, nonprofit, active military, and private household sectors) – is another indicator for measuring each state's economy. Texas had the third-highest change in nonfarm payrolls from 2022 to 2023, according to WalletHub, behind Nevada and Florida.

Although the overall state of Texas' economy may be strong, that doesn't guarantee all Texans will reap the benefits from that success. WalletHub analyst Cassandra Happe explained there's more to improving state residents' financial success than just relying on the economy.

"Factors like a low unemployment rate and high average income help residents purchase property, pay down debt and save for the future," Happe said. "The best state economies also encourage growth by being friendly to new businesses and investing in new technology that will help the state deal with future challenges and become more efficient."

On the other end of the economic scale, Hawaii and Mississippi flopped with the worst state economies in the U.S. in 2024, ranking No. 50 and No. 51, respectively.

The top 10 states with the best economies are:

  • No. 1 – Washington
  • No. 2 – Utah
  • No. 3 – Massachusetts
  • No. 4 – Texas
  • No. 5 – California
  • No. 6 – Colorado
  • No. 7 – Florida
  • No. 8 – North Carolina
  • No. 9 – District of Columbia
  • No. 10 – Arizona
The full report can be found on wallethub.com

.

------

This article originally ran on CultureMap.

From Your Site Articles
New study found that Texas has the 9th largest economy. Photo by gguy44/Getty Images

Report: Lone Star State snags spot as world's 9th largest economy by GDP

go texas

If Texas were a country — and plenty of Texans wish that were the case — it would rank among the world's 10 largest economies. Economic development officials are now touting that fact as evidence of Houston and the rest of Texas being a great place to start or relocate a business.

In a January 27 news release, the nonprofit Texas Economic Development Corp. noted that based on 2019 data from the International Monetary Fund, Texas would boast the world's ninth largest economy if it were a country. The news release lists the state's gross domestic product, or GDP — a key indicator of economic size and strength — as $1.9 trillion.

Texas' GDP would put it ahead of 10th-place Brazil ($1.8 trillion GDP, based on 2019 data from the International Monetary Fund) and behind eighth-place Italy ($2 trillion GDP), the economic development group says. Previously, Texas had ranked 10th for GDP when compared with countries.

If you dig deeper into the data, the competition between Texas and Brazil is even closer than the news release reveals. Texas' 2019 GDP stood at $1.844 trillion, giving it a razor-thin edge over Brazil ($1.839 trillion). Nonetheless, Texas beats Brazil in terms of economic strength.

It turns out that the Houston metro area contributes about one-fourth of Texas' GDP. In 2019, the region's GDP stood at $472.1 billion. The size of Houston's economy ranks seven among U.S. metro areas. If the Houston metro area were a state, it would rank 15th for GDP.

In the wake of last year's pandemic-clobbered economy, the Greater Houston Partnership predicts the region will add 35,000 to 52,000 net new jobs this year.

"The virus has dealt this region a significant blow, and the reality is it will take many months — if not years — to regain the jobs lost and repair the damage," Bob Harvey, president and CEO of the partnership, said in December. "We have our work cut out for us in growing our economy out of the hole it is currently in. But we are Houston and I believe we will recover. We will continue to work to make this a truly global city, one with a strong, diverse, 21st century economy that provides a great quality of life and opportunity for all."

While the pandemic has strained the state's economy as a whole, the International Monetary Fund estimates Texas should maintain the No. 9 spot for GDP in 2021 when stacked against countries. Texas would be wedged between No. 8 France ($2.1 trillion GDP) and No. 9 Canada ($1.76 trillion GDP). This year, the U.S. GDP is projected to remain the world's largest ($21.9 trillion), with China in second place (nearly $16.5 trillion).

"This is more than just a statistic. The fact that our state, if it were a nation, would be the world's ninth largest economy shows that Texas is well positioned to outperform economically, regardless of the challenges that may lie ahead," Robert Allen, president and CEO of the Texas Economic Development Corp., says in the release.

Allen's group cites the pending move of Hewlett Packard Enterprise's headquarters from Silicon Valley to the Houston suburb of Spring as one factor demonstrating the power of Texas' economy.

"Why come to Texas from other states? Our highly competitive tax climate, world-class infrastructure, a skilled workforce of 14 million people, business-friendly economic policies, and abundant quality of life," Allen says. "Texas obviously has a lot to offer. Our standing as the world's ninth largest economy and our long-term expansion shows that Texas also offers rock-solid stability to companies that want to locate here."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings